Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05891743
Other study ID # LOD_VAG_011
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date March 8, 2024
Est. completion date August 7, 2024

Study information

Verified date March 2024
Source Siemens Gamesa Renewable Energy Blades, S.A.
Contact Andreia Marques, PhD
Phone +351 936 766 893
Email ANDREIA.MARQUES.ext@siemensgamesa.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The goal of this observational study it to learn about the prevalence of skin sensitization and dermatitis among epoxy-exposed workers in the wind turbine industry. The main question it aims to answer is: - What is the prevalence of skin sensitization and dermatitis among workers in the wind turbine industry who are exposed to epoxy? Participants will be asked to perform Patch Test, which is considered the Gold Standard test for identifying the cause of occupational contact allergic dermatitis. Researchers will compare the results of the epoxy-exposed group with those of a control group comprising non-exposed workers from the same industry. This analysis will help determine if there is a higher prevalence of skin sensitization among workers exposed to epoxy.


Description:

Epoxy resin systems are widely used materials in various industries due to their high mechanical, chemical, and thermal resistance. These systems are commonly employed as protective coatings, adhesives, and paints, as well as in the manufacturing of composites in the plastics industry. Epoxy components are well-known sensitizers of the skin. A high prevalence of skin sensitization and dermatitis have been reported among workers exposed to epoxy components. It is recommended to use comprehensive protective equipment when handling epoxy components. In the wind turbine industry, tasks involving epoxy handling, such as lamination and filling procedures, are frequently performed. Recent study have shown a sensitization prevalence of 8.9% among workers performing these tasks, while a previous study reported a high sensitization rate of 10.5% to epoxy resins. Despite efforts to find alternatives to epoxy resin systems and improve protective measures, the use of epoxy has increased, and some countries have implemented more stringent regulations, such as Denmark. In Portugal, there are currently no specific regulations regarding epoxy handling, and no certification is required for working with epoxy. Siemens Gamesa Renewable Energy, in Portugal, faces many skin problems among production workers, however numbers are unknown. Therefore, the main purpose of the study is to evaluate the prevalence of skin sensitization and dermatitis among epoxy-exposed workers in the wind Turbine Industry.


Recruitment information / eligibility

Status Recruiting
Enrollment 150
Est. completion date August 7, 2024
Est. primary completion date August 7, 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - Workers from the wind turbine industry Exclusion Criteria: - Pregnant females - Workers previously diagnosed with epoxy resin sensitization

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Patch Test
The Patch Test will include the European baseline series, as well as the epoxy and isocyanate series. Additionally, specific products commonly used in the workplace, such as glues, resins, and paints, will be prepared and included in the testing.

Locations

Country Name City State
Portugal Siemens Gamesa Renewable Energy (SGRE) Aveiro Soza

Sponsors (2)

Lead Sponsor Collaborator
Siemens Gamesa Renewable Energy Blades, S.A. Association for Innovation and Biomedical Research on Light and Image

Country where clinical trial is conducted

Portugal, 

References & Publications (5)

Aalto-Korte K, Pesonen M, Suuronen K. Occupational allergic contact dermatitis caused by epoxy chemicals: occupations, sensitizing products, and diagnosis. Contact Dermatitis. 2015 Dec;73(6):336-42. doi: 10.1111/cod.12445. Epub 2015 Jul 30. — View Citation

Christiansen AG, Carstensen O, Sommerlund M, Clausen PA, Bonlokke JH, Schlunssen V, Isaksson M, Schmidt SAJ, Kolstad HA. Prevalence of skin sensitization and dermatitis among epoxy-exposed workers in the wind turbine industry. Br J Dermatol. 2022 Dec;187(6):988-996. doi: 10.1111/bjd.21830. Epub 2022 Sep 16. — View Citation

Geier J, Lessmann H, Hillen U, Skudlik C, Jappe U. Sensitization to reactive diluents and hardeners in epoxy resin systems. IVDK data 2002-2011. Part II: concomitant reactions. Contact Dermatitis. 2016 Feb;74(2):94-101. doi: 10.1111/cod.12490. Epub 2015 Nov 5. — View Citation

Ponten A, Carstensen O, Rasmussen K, Gruvberger B, Isaksson M, Bruze M. Epoxy-based production of wind turbine rotor blades: occupational contact allergies. Dermatitis. 2004 Mar;15(1):33-40. doi: 10.2310/6620.2004.20433. — View Citation

Prodi A, Rui F, Fortina AB, Corradin MT, Filon FL. Occupational sensitization to epoxy resins in Northeastern Italy (1996-2010). Int J Occup Environ Health. 2015;21(1):82-7. doi: 10.1179/2049396714Y.0000000095. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Prevalence of skin sensitization. Allergens will be applied to the participant's back using IQ Chambers® (Chemotechnique) and secured with 4fix® adhesive tape for 48 hours. Readings will be conducted on day 2-3 and, if necessary, on days 4-7, following the ESCD guidelines. 2-3 days
See also
  Status Clinical Trial Phase
Completed NCT03563066 - Effect of Benralizumab in Atopic Dermatitis Phase 2
Completed NCT02916888 - A Study Comparing the Quality of Life of Patients in the Treatment of Eczema by Pediatric Generalists and Specialists N/A
Recruiting NCT01631617 - Effects of Treatments on Atopic Dermatitis Phase 2
Completed NCT03720470 - Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy Phase 3
Recruiting NCT01012453 - A Randomised Clinical Trial in a Population of Health Care Workers With Hand Eczema N/A
Completed NCT00375713 - Randomized Phase III Study to Evaluate the Efficacy and Safety of Xyzal® (Levocetirizine) vs Zyrtec® (Cetirizine) in Subjects With Dermatitis and Eczema Phase 3
Completed NCT00001150 - Induction of Suction Blisters in Patients With Urticaria, Blistering Diseases, Inflammatory Dermatoses and Neoplastic Disorders, and in Normal Volunteers N/A
Completed NCT05247333 - Implementation of a Minor Ailment Service in Community Pharmacy Practice N/A
Withdrawn NCT04154033 - Treatment of Chronic Itch in Atopic Dermatitis With Topical Naltrexone Phase 2
Completed NCT02979210 - Infant Fecal Insult Study N/A
Completed NCT02615912 - A Single-Center, Exploratory Study to Analyze the Dynamics of Skin Microflora Following Exposure to Surfactants N/A
Withdrawn NCT01125761 - Efficacy and Safety of the Association Drugs in Patients With Allergic Dermatitis Phase 3
Withdrawn NCT00746382 - A Placebo Controlled 4 Week Proof of Concept Study With 0.5% Roflumilast Cream in Patients With Mild Atopic Dermatitis (RO-2351-001-EM) Phase 2
Terminated NCT00176956 - Atopic Dermatitis-Like Skin Disease in Pediatric Heart Transplant Patients Phase 3
Completed NCT05001139 - Clinical Investigation on the Efficacy and Safety of Relizema Ecofoam N/A
Completed NCT00801502 - Salmon in Pregnancy Study N/A
Completed NCT00005781 - Assessment of Digital Imaging as a Tool for Diagnosing Psoriasis, Hand Rashes and Unusual Moles N/A
Completed NCT05324618 - Tacrolimus Versus Hydrocortisone in Atopic Dermatitis Phase 4
Completed NCT04826471 - Clinical Investigation on the Performance and Safety of DermoRelizema Ecofoam N/A
Completed NCT01840605 - A Confirmatory Study of TAU-284 in Pediatric Patients With Atopic Dermatitis Phase 3